Search hospitals
>
Wisconsin
>
Green Bay
Saint Vincent Hospital Cancer Center Green Bay
Claim this profile
Green Bay, Wisconsin 54301
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Leukemia
506 reported clinical trials
5 medical researchers
Summary
Saint Vincent Hospital Cancer Center Green Bay is a medical facility located in Green Bay, Wisconsin. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Leukemia and other specialties. Saint Vincent Hospital Cancer Center Green Bay is involved with conducting 506 clinical trials across 584 conditions. There are 5 research doctors associated with this hospital, such as Matthew L. Ryan, Brian L. Burnette, Anthony J. Jaslowski, and Catherine A. Long.
Area of expertise
Breast Cancer
Saint Vincent Hospital Cancer Center Green Bay has run 101 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Saint Vincent Hospital Cancer Center Green Bay has run 74 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Matthew L. Ryan
Saint Vincent Hospital Cancer Center Green Bay
2 years of reported clinical research
Brian L. Burnette
Saint Vincent Hospital Cancer Center Green Bay
5 years of reported clinical research
Anthony J. Jaslowski
Saint Vincent Hospital Cancer Center Green Bay
7 years of reported clinical research
Catherine A. Long
Saint Vincent Hospital Cancer Center Green Bay
6 years of reported clinical research
Clinical Trials running at Saint Vincent Hospital Cancer Center Green Bay
Lung Cancer
Breast Cancer
Breast cancer
Esophageal cancer
Cancer
Bladder Cancer
Ovarian Cancer
Acute Myeloid Leukemia
Non-Small Cell Lung Cancer
Colorectal Cancer
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting
2 awards
Phase 3
8 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Saint Vincent Hospital Cancer Center Green Bay?
Saint Vincent Hospital Cancer Center Green Bay is a medical facility located in Green Bay, Wisconsin. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Leukemia and other specialties. Saint Vincent Hospital Cancer Center Green Bay is involved with conducting 506 clinical trials across 584 conditions. There are 5 research doctors associated with this hospital, such as Matthew L. Ryan, Brian L. Burnette, Anthony J. Jaslowski, and Catherine A. Long.
Where is Saint Vincent Hospital Cancer Center Green Bay located?
The Saint Vincent Hospital Cancer Center is located at 835 S Van Buren St, Green Bay, Wisconsin 54301.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Saint Vincent Hospital Cancer Center in Green Bay, reach out to the financial counselors at (216) 694-4652 or (216) 694-4653. They will assess eligibility for free or discounted care based on income, family size, and financial changes, in line with the Financial Assistance Policy. For insurance inquiries, visit the Insurances Accepted page on the hospital's website or call the hospital directly at (920) 433-0111 for more information.
What insurance does Saint Vincent Hospital Cancer Center Green Bay accept?
The Saint Vincent Hospital Cancer Center in Green Bay, Wisconsin, is affiliated with HSHS St. Vincent, St. Mary's, St. Nicholas, St. Clare Memorial hospitals, and Libertas, accepting a wide range of insurance plans. These include commercial insurance, managed Medicaid, Medicare Advantage, and Health Insurance Exchange plans. For detailed information on accepted insurance plans, contacting the hospital directly is advised.
What awards or recognition has Saint Vincent Hospital Cancer Center Green Bay received?
The Saint Vincent Hospital Cancer Center, located in Green Bay, Wisconsin, is renowned for its exceptional cancer care and research. It has conducted over 1,100 clinical trials involving more than 5,300 patients through its Clinical Research Institute. The center is affiliated with the National Cancer Institute and has been recognized for outstanding achievement in cancer care and research.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.